Abstract: Disclosed herein is a document destruction lid for preventing the retrieval of documents inserted through the lid. The lid comprises a skirt extending around a periphery of the lid for securing the lid to a container. A vertical sidewall extending downward from a top surface of the lid, having a height greater than or equal to 70% of a height of a lip of the container. A security structure for depositing the documents extends from a top surface of the lid. The security structure comprises a front wall, a horizontal slot, a rear wall extending upwards from the top surface of the lid opposite the front wall, and a top surface joining the front wall to the rear wall. The front wall and rear wall are angled away from each other to make document retrieval difficult while still allowing easy disposal of the documents.

Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory anti-KLK5 antibodies and their use in the treatment of Netherton disease, atopic dermatitis and cancer.

Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory antibodies binding KLK5 and their use in the treatment of Netherton disease, atopic dermatitis and cancer.

Abstract: Disclosed herein is a document destruction lid for preventing the retrieval of documents inserted through the lid. The lid comprises a skirt extending around a periphery of the lid for securing the lid to a container. A vertical sidewall extending downward from a top surface of the lid, having a height greater than or equal to 70% of a height of a lip of the container. A security structure for depositing the documents extends from a top surface of the lid. The security structure comprises a front wall, a horizontal slot, a rear wall extending upwards from the top surface of the lid opposite the front wall, and a top surface joining the front wall to the rear wall. The front wall and rear wall are angled away from each other to make document retrieval difficult while still allowing easy disposal of the documents.

Abstract: Advantageous online and/or real-time OFDM-based underwater acoustic (UWA) apparatus, systems and methods are provided according to the present disclosure. The apparatus, systems and methods employ a receiver with a bank of parallel branches, with each branch having a self-correlator matched to a different waveform scaling factor. A detection is declared when any of the branches leads to a correlation metric larger than a pre-defined threshold. The branch with the largest metric yields a Doppler scale estimate and a coarse synchronization point. The proposed apparatus, systems and methods use one OFDM preamble, thereby avoiding the need to buffer the whole data packet before data demodulation and enabling online and/or real-time operation. Thus, the disclosed apparatus, systems and methods are advantageously applicable to UWA communications.

Abstract: Advantageous online and/or real-time OFDM-based underwater acoustic (UWA) apparatus, systems and methods are provided according to the present disclosure. The apparatus, systems and methods employ a receiver with a bank of parallel branches, with each branch having a self-correlator matched to a different waveform scaling factor. A detection is declared when any of the branches leads to a correlation metric larger than a pre-defined threshold. The branch with the largest metric yields a Doppler scale estimate and a coarse synchronization point. The proposed apparatus, systems and methods use one OFDM preamble, thereby avoiding the need to buffer the whole data packet before data demodulation and enabling online and/or real-time operation. Thus, the disclosed apparatus, systems and methods are advantageously applicable to UWA communications.

Abstract: The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are isolated peptides incorporating epitopes or mimotopes of surface exposed regions of the C?2 domain of IgE. The inventors have found that these novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the surface exposed IgE regions of the present invention, and their use in medicine as passive immunotherapy or in immunoprophylaxis.

Abstract: The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are epitopes or mimotopes derived from the C?3 or C?4 domains of IgE. These novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human heparanase, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract: The present invention relates to a novel chemical process for the covalent conjugation of disulphide bridge cyclised peptides to immunogenic carrier molecules by thio-ether linkages to form vaccine immunogens. In particular, the novel chemistry involves reacting a thiolated carrier with a cyclic peptide containing a disulphide bridge, which cylcic peptide (herein a disulphide bridge cyclised peptide) has attached to it, usually via a linker, a reactive group capable for forming thio-ether bonds with the carrier. The invention further related to activated peptide intermediates of the process, medicaments produced by the process, pharmaceutical compositions containing the medicaments, and the use of the pharmaceutical compositions in medicine. The process of the present invention is particularly useful for the preparation of highly pure immunogens for vaccines, comprising disulphide bridge cyclised peptides.

Abstract: The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are epitopes or mimotopes derived from the C&egr;3 or C&egr;4 domains of IgE. These novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.

Abstract: The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are epitopes or mimotopes derived from the C&egr;3 or C&egr;4 domains of IgE. These novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.